GlassScriptPhysician profile
James Marcus Wilder
NPI 1942298609
$5,906.95
in general payments reported to CMS, 2019-2025
27 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $720 · 2022: $933 · 2023: $1,281 · 2024: $1,372 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,254.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,352.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $555.31 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $416.90 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $290.09 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $289.54 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Bodyguardian |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.83 | 2023-2025 | Caplyta |
| Pfizer INC. | $232.28 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $223.70 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $179.56 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $169.66 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $164.07 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $129.04 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $87.96 | 2023-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $86.03 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $73.92 | 2024-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.65 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.06 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $48.33 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $45.51 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $40.58 | 2021 | |
| Esperion Therapeutics, INC. | $32.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.85 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $29.57 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $27.12 | 2022 | |
| Almatica Pharma LLC | $15.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2022 | |
| Abbott Laboratories | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.